Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Q1 2021 Correction?

<< Previous

Bullboard Posts

Next >>

Comment by Pandoraon Jan 02, 2021 12:04pm

165 Views

Post# 32209437

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Q1 2021 Correction?

Colorado, Washington and Florida all made headlines because of reporting such things as gunshot deaths as being caused by covid. I'm sure the other 47 state administrator's would never consider fudging any data even if it made a difference from a funding point of view. :-)) After all, we're all completely honest in our nature.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing